89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

NCT05423197 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Head-and-neck Squamous Cell Carcinoma

Interventions

DRUG: 89Zr-panitumumab IV
DRUG: Panitumumab

Sponsor

Stanford University